Insulin Resistance-Pipeline Review, H1 2017

Insulin Resistance-Pipeline Review, H1 2017


  • Products Id :- GMDHC9008IDB
  • |
  • Pages: 45
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Insulin Resistance-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Insulin Resistance-Pipeline Review, H1 2017, provides an overview of the Insulin Resistance (Metabolic Disorders) pipeline landscape.

Insulin resistance (IR) is a condition in which the body's cells become resistant to the effects of insulin. This occurs when insulin levels are sufficiently high over a prolonged period of time causing the body's own sensitivity to the hormone to be reduced. Symptoms include lethargy, hunger, difficulty concentrating and high blood pressure. Predisposing factors include obesity and hypertension.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Insulin Resistance-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Insulin Resistance (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Insulin Resistance (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Insulin Resistance and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 2 molecules, respectively.

Insulin Resistance (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Insulin Resistance (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Insulin Resistance (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Insulin Resistance (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Insulin Resistance (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Insulin Resistance (Metabolic Disorders)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Insulin Resistance (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Insulin Resistance (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Insulin Resistance-Overview

Insulin Resistance-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Insulin Resistance-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Insulin Resistance-Companies Involved in Therapeutics Development

Amgen Inc

AusBio Ltd

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

Hadasit Medical Research Services & Development Ltd

Pfizer Inc

Prometheon Pharma LLC

Sanofi

Insulin Resistance-Drug Profiles

ATA-842-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

englerin A-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FC-98-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

L-2286-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MD-960-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MD-961-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Agonize Oxytocin Receptor for Obesity and Insulin Resistance-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-7992-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-088-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sildenafil citrate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Atherosclerosis and Insulin Resistance-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit AMPD2 for Hypertension and Metabolic Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target AGTR1 and PPAR Gamma for Hypertension and Insulin Resistance-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit TRIP-Br2 for Obesity and Insulin Resistance-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYM-401-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TM-25659-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Insulin Resistance-Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Insulin Resistance, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Insulin Resistance, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Insulin Resistance-Pipeline by Amgen Inc, H1 2017

Insulin Resistance-Pipeline by AusBio Ltd, H1 2017

Insulin Resistance-Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Insulin Resistance-Pipeline by GlaxoSmithKline Plc, H1 2017

Insulin Resistance-Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2017

Insulin Resistance-Pipeline by Pfizer Inc, H1 2017

Insulin Resistance-Pipeline by Prometheon Pharma LLC, H1 2017

Insulin Resistance-Pipeline by Sanofi, H1 2017

Insulin Resistance-Dormant Projects, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Amgen Inc, AusBio Ltd, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Hadasit Medical Research Services & Development Ltd, Pfizer Inc, Prometheon Pharma LLC, Sanofi

Insulin Resistance Therapeutic Products under Development, Key Players in Insulin Resistance Therapeutics, Insulin Resistance Pipeline Overview, Insulin Resistance Pipeline, Insulin Resistance Pipeline Assessment

select a license
Single User License
USD 2000 INR 146460
Site License
USD 4000 INR 292920
Corporate User License
USD 6000 INR 439380

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com